Xenon Pharmaceuticals Inc. (XENE)
NASDAQ: XENE · Real-Time Price · USD
60.56
-0.21 (-0.35%)
Aug 24, 2026, 4:00 PM EDT - Market closed
Xenon Pharmaceuticals Employees
As of December 31, 2025, Xenon Pharmaceuticals had 370 total employees, including 358 full-time and 12 part-time employees. The number of employees increased by 43 or 13.15% compared to the previous year.
Employees
370
Change (1Y)
43
Growth (1Y)
13.15%
Revenue / Employee
n/a
Profits / Employee
-$1,105,932
Market Cap
5.86B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 370 | 43 | 13.15% | 358 | 12 |
| Dec 31, 2024 | 327 | 68 | 26.25% | 316 | 11 |
| Dec 31, 2023 | 259 | 46 | 21.60% | 251 | 8 |
| Dec 31, 2022 | 213 | 60 | 39.22% | 203 | 10 |
| Dec 31, 2021 | 153 | 24 | 18.60% | 149 | 4 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| PTC Therapeutics | 991 |
| ACADIA Pharmaceuticals | 798 |
| Travere Therapeutics | 497 |
| Mirum Pharmaceuticals | 433 |
| CRISPR Therapeutics AG | 393 |
| Cogent Biosciences | 258 |
| Definium Therapeutics | 106 |
| Erasca | 103 |
XENE News
- 17 days ago - Xenon Pharmaceuticals price target lowered to $81 from $82 at RBC Capital - TheFly
- 18 days ago - Xenon Pharmaceuticals Earnings Call Transcript: Q2 2026 - Transcripts
- 18 days ago - Xenon Pharmaceuticals Earnings release: Q2 2026 - Filings
- 18 days ago - Xenon Pharmaceuticals Quarterly report: Q2 2026 - Filings
- 18 days ago - Xenon Pharmaceuticals reports Q2 EPS ($1.11), consensus ($1.16) - TheFly
- 18 days ago - Xenon Reports Q2 2026 Financial Results and Provides Business Update - GlobeNewsWire
- 24 days ago - Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 25 days ago - Xenon to Report Q2 2026 Financial Results on August 6, 2026 - GlobeNewsWire